{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:05:19Z","timestamp":1790867119865,"version":"4.1.0"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>An animal model that mimics progressive disseminated vaccinia was elaborated. To this end nude (athymic) mice were inoculated intracutaneously with vaccinia virus in the lumbosacral area. Viral replication (DNA) in the skin was detected as early as day 2 postinfection (p.i.). Mice developed typical vaccinia lesions at the site of inoculation by day 4 to 6 p.i. By about 2 weeks p.i., the infection had spread all over the body, a situation reminiscent of disseminated vaccinia in humans. The infection resulted in viremia and spread of the virus to visceral organs, as well as to the brain. Topical treatment with cidofovir, initiated at the day of infection or at day 1 p.i., completely protected against virus-induced cutaneous lesions and against associated mortality. When treatment was initiated at a later time (day 2 to 5 p.i.), a partial but marked protective effect was noted, which can be explained by the fact that by that time, the virus had spread from the skin to the visceral organs. Next, infected animals were left untreated until the time (\u223c2 weeks p.i.) at which disseminated vaccinia had developed. When systemic treatment with cidofovir was initiated at that time, it caused lesions to heal and regress. In most of these animals, lesions had completely (or almost completely) disappeared by day 10 to 15 after the start of therapy. The observation that cidofovir is able to cause healing of disseminated vaccinia lesions in animals should have implications for the therapy of complications of vaccination against smallpox.<\/jats:p>","DOI":"10.1128\/aac.48.6.2267-2273.2004","type":"journal-article","created":{"date-parts":[[2004,5,21]],"date-time":"2004-05-21T18:38:42Z","timestamp":1085164722000},"page":"2267-2273","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":59,"title":["Efficacy of Cidofovir in a Murine Model of Disseminated Progressive Vaccinia"],"prefix":"10.1128","volume":"48","author":[{"given":"Johan","family":"Neyts","sequence":"first","affiliation":[{"name":"Rega Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Leyssen","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Verbeken","sequence":"additional","affiliation":[{"name":"Division of Histopathology, University Hospitals, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"De Clercq","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/jps.2600840617","volume":"84","year":"1995","unstructured":"Aspe, E., R. H. Guy, W. A. Lee, J. A. Kennedy, G. C. Visor, and R. D. Ennis. 1995. Optimization of in vitro flux through hairless mouse skin of cidofovir, a potent nucleotide analog. J. Pharm. Sci.84:750-754.","journal-title":"J. Pharm. Sci."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(03)00008-1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/374244"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(01)00220-0"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/315190"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020025"},{"key":"e_1_3_2_8_2","first-page":"819","volume":"52","year":"2003","unstructured":"Centers for Disease Control and Prevention. 2003. Update: adverse events following civilian smallpox vaccination\u2014United States, 2003. Morb. Mortal. Wkly. Rep.52:819-820.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/bmj.327.7412.414","volume":"327","year":"2003","unstructured":"Charatan, F. 2003. US panel advises caution over smallpox vaccination. BMJ327:414.","journal-title":"BMJ"},{"key":"e_1_3_2_10_2","first-page":"745","volume":"24","year":"1996","unstructured":"Cundy, K. C., A. M. Bidgood, G. Lynch, J. P. Shaw, L. Griffin, and W. A. Lee. 1996. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Dispos.24:745-752.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_11_2","first-page":"738","volume":"24","year":"1996","unstructured":"Cundy, K. C., Z. H. Li, M. J. Hitchcock, and W. A. Lee. 1996. Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metab. Dispos.24:738-744.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.6.1247"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.2.382-397.2001"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0165-6147(02)02091-6","volume":"23","year":"2002","unstructured":"De Clercq, E. 2002. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci.23:456-458.","journal-title":"Trends Pharmacol. Sci."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.128052"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1126\/science.298.5602.2313","volume":"298","year":"2002","unstructured":"Enserink, M. 2002. Public health. Treating vaccine reactions: two lifelines, but no guarantees. Science298:2313.","journal-title":"Science"},{"key":"e_1_3_2_17_2","first-page":"486","volume":"299","year":"2003","unstructured":"Enserink, M. 2003. Go slow with smallpox shots, panel says. Science299:486-487.","journal-title":"Science"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013431"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/375824"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/375825"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1084"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(96)00163-6"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/000155500750012333","volume":"80","year":"2000","unstructured":"Ibarra, V., J. R. Blanco, J. A. Oteo, and L. Rosel. 2000. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. Acta Derm. Venereol.80:315-316.","journal-title":"Acta Derm. Venereol."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.162282799"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890440061010"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890410312"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.84-87.2001"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0166-3542(02)00197-3","volume":"57","year":"2003","unstructured":"Neyts, J., and E. De Clercq. 2003. Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antivir. Res.57:25-33.","journal-title":"Antivir. Res."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.2842-2847.2002"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703123161106"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632020101200105"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(00)00105-4"},{"key":"e_1_3_2_33_2","first-page":"983","volume":"136","year":"2000","unstructured":"Toro, J. R., L. V. Wood, N. K. Patel, and M. L. Turner. 2000. Topical cidofovir. A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch. Dermatol.136:983-985.","journal-title":"Arch. Dermatol."},{"key":"e_1_3_2_34_2","first-page":"1","volume":"52","year":"2003","unstructured":"Wharton, M., R. A. Strikas, R. Harpaz, L. D. Rotz, B. Schwartz, C. G. Casey, M. L. Pearson, and L. J. Anderson. 2003. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Morb. Mortal. Wkly. Rep. Recomm. Rep.52(RR-7):1-16.","journal-title":"Morb. Mortal. Wkly. Rep. Recomm. Rep."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1046\/j.1525-1470.1999.016005406.7.x","volume":"16","year":"1999","unstructured":"Zabawski, E. J., and C. J. Cockerell. 1999. Topical cidofovir for molluscum contagiosum in children. Pediatr. Dermatol.16:414-415.","journal-title":"Pediatr. Dermatol."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.6.2267-2273.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.6.2267-2273.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T13:14:54Z","timestamp":1705151694000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.6.2267-2273.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1128\/AAC.48.6.2267-2273.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.6.2267-2273.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]},"assertion":[{"value":"2003-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-02-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}